In vivo correlation of serotonin transporter and 1B receptor availability in the human brain: a PET study.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
31
01
2022
accepted:
15
06
2022
revised:
13
06
2022
pubmed:
13
7
2022
medline:
16
8
2022
entrez:
12
7
2022
Statut:
ppublish
Résumé
Synaptic serotonin levels in the brain are regulated by active transport into the bouton by the serotonin transporter, and by autoreceptors, such as the inhibitory serotonin (5-HT) 1B receptor which, when activated, decreases serotonin release. Animal studies have shown a regulatory link between the two proteins. Evidence of such coupling could translate to an untapped therapeutic potential in augmenting the effect of selective serotonin reuptake inhibitors through pharmacological modulation of 5-HT
Identifiants
pubmed: 35821068
doi: 10.1038/s41386-022-01369-3
pii: 10.1038/s41386-022-01369-3
pmc: PMC9372190
doi:
Substances chimiques
Receptor, Serotonin, 5-HT1B
0
Serotonin Plasma Membrane Transport Proteins
0
Serotonin Uptake Inhibitors
0
Serotonin
333DO1RDJY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1863-1868Informations de copyright
© 2022. The Author(s).
Références
World Health Organization. Global Health Estimates 2016: Disease burden by Cause, Age, Sex, by Country and by Region, 2000–2016. Geneva; 2018.
Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969;293:132–6.
doi: 10.1016/S0140-6736(69)91140-4
Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12:2–19.
pubmed: 11098410
doi: 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4
Hamel E, Currents H. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27:1293–1300.
pubmed: 17970989
doi: 10.1111/j.1468-2982.2007.01476.x
The National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. 2011.
Warden D, Rush A, Trivedi M, Fava M, Wisniewski S. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2008;9:449–59.
doi: 10.1007/s11920-007-0061-3
Lundberg J, Tiger M, Landén M, Halldin C, Farde L. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15:1167–72.
pubmed: 22243688
doi: 10.1017/S1461145711001945
Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol. 2019;21:18.
pubmed: 30895388
doi: 10.1007/s11940-019-0557-2
The National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. 2012.
Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, et al. Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. Neuropsychopharmacology. 2019;44:1706–13.
pubmed: 31216565
pmcid: 6784989
doi: 10.1038/s41386-019-0442-4
Tiger M, Varnäs K, Okubo Y, Lundberg J. The 5-HT(1B) receptor - a potential target for antidepressant treatment. Psychopharmacol (Berl). 2018;235:1317–34.
doi: 10.1007/s00213-018-4872-1
The Swedish National Board of Health and Welfare. Statisticals on Pharmaceuticals 2019. 2020:2020-4–6708. https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikdatabasen/ .
Ruf MB, Bhagwagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets. 2009;10:1118–38.
pubmed: 19702551
doi: 10.2174/138945009789735192
Charnay Y, Léger L. Brain serotonergic circuitries. Dialogues Clin Neurosci. 2010;12:471–87.
pubmed: 21319493
pmcid: 3181988
doi: 10.31887/DCNS.2010.12.4/ycharnay
Hagan CE, McDevitt RA, Liu Y, Furay AR, Neumaier JF. 5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse 2012;66:1024–34.
pubmed: 22961814
pmcid: 3472085
doi: 10.1002/syn.21608
Montañez S, Munn JL, Owens WA, Horton RE, Daws LC. 5-HT1B receptor modulation of the serotonin transporter in vivo: Studies using KO mice. Neurochem Int. 2014;73:127–31.
pubmed: 24246466
doi: 10.1016/j.neuint.2013.11.004
Anthony JP, Sexton TJ, Neumaier JF. Antidepressant-induced regulation of 5-HT1b mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci Res. 2000;61:82–87.
pubmed: 10861803
doi: 10.1002/1097-4547(20000701)61:1<82::AID-JNR10>3.0.CO;2-E
Nord M, Cselenyi Z, Forsberg A, Rosenqvist G, Tiger M, Lundberg J, et al. Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain. Neuroimage 2014;103:303–8.
pubmed: 25255943
doi: 10.1016/j.neuroimage.2014.09.040
Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2008;24:513–20.
pubmed: 18832428
doi: 10.1177/0269881108097714
Beliveau V, Ozenne B, Strother S, Greve DN, Svarer C, Knudsen GM, et al. The structure of the serotonin system: A PET imaging study. Neuroimage 2020;205:116240.
pubmed: 31600591
doi: 10.1016/j.neuroimage.2019.116240
Lundberg J, Borg J, Halldin C, Farde LA. PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain. Psychopharmacol (Berl). 2007;195:425–33.
doi: 10.1007/s00213-007-0928-3
Strupp-Levitsky M, Miller JM, Rubin-Falcone H, Zanderigo F, Milak MS, Sullivan G, et al. Lack of association between the serotonin transporter and serotonin 1A receptor: an in vivo PET imaging study in healthy adults. Psychiatry Res Neuroimaging. 2016;255:81–86.
pubmed: 27567324
doi: 10.1016/j.pscychresns.2016.08.002
Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnäs K, et al. [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 2008;41:1075–85.
pubmed: 18434202
doi: 10.1016/j.neuroimage.2008.02.063
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.
pubmed: 9881538
Svensson JE, Svanborg C, Plavén-Sigray P, Kaldo V, Halldin C, Schain M, et al. Serotonin transporter availability increases in patients recovering from a depressive episode. Transl Psychiatry. 2021;11:264.
pubmed: 33972499
pmcid: 8110529
doi: 10.1038/s41398-021-01376-w
Halldin C, Lundberg J, Sóvágó J, Gulyás B, Guilloteau D, Vercouillie J, et al. [11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse. 2005;58:173–83.
pubmed: 16138320
doi: 10.1002/syn.20189
Varrone A, Sjöholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639–50.
pubmed: 19437012
doi: 10.1007/s00259-009-1156-3
Fischl B. FreeSurfer. Neuroimage. 2012;62:774–81.
pubmed: 22248573
doi: 10.1016/j.neuroimage.2012.01.021
Varnäs K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2010;31:113–23.
pubmed: 20424633
pmcid: 3049476
doi: 10.1038/jcbfm.2010.55
Iglesias JE, Van Leemput K, Bhatt P, Casillas C, Dutt S, Schuff N, et al. Bayesian segmentation of brainstem structures in MRI. Neuroimage 2015;113:184–95.
pubmed: 25776214
doi: 10.1016/j.neuroimage.2015.02.065
Matheson GJ, Stenkrona P, Cselényi Z, Plavén-Sigray P, Halldin C, Farde L, et al. Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390. Neuroimage. 2017;155:344–53.
pubmed: 28419852
doi: 10.1016/j.neuroimage.2017.04.031
Schain M, Tóth M, Cselényi Z, Arakawa R, Halldin C, Farde L, et al. Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT. Eur J Nucl Med Mol Imaging. 2013;40:228–37.
pubmed: 23076621
doi: 10.1007/s00259-012-2260-3
Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.
pubmed: 9345505
doi: 10.1006/nimg.1996.0066
Nørgaard M, Ganz M, Svarer C, Frokjaer VG, Greve DN, Strother SC, et al. Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [11C]DASB PET study. Neuroimage. 2019;199:466–79.
pubmed: 31158479
doi: 10.1016/j.neuroimage.2019.05.055
Svensson JE, Schain M, Plavén-Sigray P, Cervenka S, Tiger M, Nord M, et al. Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain. Neuroimage. 2019;202:116143.
pubmed: 31473354
doi: 10.1016/j.neuroimage.2019.116143
Lundberg J, Odano I, Olsson H, Halldin C, Farde L. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med. 2005;46:1505–15.
pubmed: 16157534
Cselényi Z, Olsson H, Farde L, Gulyás B. Wavelet-Aided Parametric Mapping of Cerebral Dopamine D 2 Receptors Using the High Affinity PET Radioligand FLB 457. Neuroimage. 2002;17:47–60.
pubmed: 12482067
doi: 10.1006/nimg.2002.1152
Schain M, Tóth M, Cselényi Z, Arakawa R, Halldin C, Farde L, et al. Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT. Eur J Nucl Med Mol Imaging. 2013;40:228–37. https://doi.org/10.1007/s00259-012-2260-3 .
Evans AC, Collins DL, Mills SR, Brown ED, Kelly RL, Peters TM 3D statistical neuroanatomical models from 305 MRI volumes. 1993 IEEE Conf. Rec. Nucl. Sci. Symp. Med. Imaging Conf., 1993. p. 1813–7 vol. 3.
Perezgonzalez JD. Fisher, Neyman-Pearson or NHST? A tutorial for teaching data testing. Front Psychol. 2015;6:223.
pubmed: 25784889
pmcid: 4347431
doi: 10.3389/fpsyg.2015.00223
Swinscow TDV Statistics at Square One. Ninth EditBMJ Publishing Group 1997; 1997.
Karrer TM, McLaughlin CL, Guaglianone CP, Samanez-Larkin GR. Reduced serotonin receptors and transporters in normal aging adults: a meta-analysis of PET and SPECT imaging studies. Neurobiol Aging. 2019;80:1–10.
pubmed: 31055162
pmcid: 6679764
doi: 10.1016/j.neurobiolaging.2019.03.021
Kim S. ppcor: An R package for a fast calculation to semi-partial correlation coefficients. Commun Stat Methods. 2015;22:665–74.
Varnäs K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004;22:246–60.
pubmed: 15195291
pmcid: 6872082
doi: 10.1002/hbm.20035
Pranzatelli MR, Durkin MM, Farmer M. Plastic responses of neonatal 5-hydroxytryptamine1B receptors to 5,7-dihydroxytryptamine lesions mapped by quantitative autoradiography. Int J Dev Neurosci. 1996;14:621–9.
pubmed: 8930693
doi: 10.1016/0736-5748(96)00029-9
Nautiyal KM, Tanaka KF, Barr MM, Tritschler L, Le Dantec Y, David DJ, et al. Distinct circuits underlie the effects of 5-HT1B receptors on aggression and impulsivity. Neuron. 2015;86:813–26.
pubmed: 25892302
pmcid: 4431594
doi: 10.1016/j.neuron.2015.03.041
Nautiyal KM, Tritschler L, Ahmari SE, David DJ, Gardier AM, Hen R. A lack of serotonin 1B autoreceptors results in decreased anxiety and depression-related behaviors. Neuropsychopharmacology. 2016;41:2941–50.
pubmed: 27353308
pmcid: 5061886
doi: 10.1038/npp.2016.109
Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol. 2002;17 Suppl 1:S1–12.
pubmed: 12369606
doi: 10.1097/00004850-200206001-00002
Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013;16:1577–86.
pubmed: 23351590
doi: 10.1017/S1461145712001617
Tiger M, Veldman ER, Ekman C-J, Halldin C, Svenningsson P, Lundberg J. A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Transl Psychiatry. 2020;10:159.
pubmed: 32475989
pmcid: 7261801
doi: 10.1038/s41398-020-0844-4
Tiger M, Gärde M, Tateno A, Matheson GJ, Sakayori T, Nogami T, et al. A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes. J Affect Disord. 2021;294:645–51.
pubmed: 34332365
doi: 10.1016/j.jad.2021.07.060
Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot J-D, Gueorguieva R, et al. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry. 2011;68:892–900.
pubmed: 21893657
pmcid: 3244836
doi: 10.1001/archgenpsychiatry.2011.91
Tiger M, Farde L, Rück C, Varrone A, Forsberg A, Lindefors N, et al. Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder. Psychiatry Res Neuroimaging. 2016;253:36–42.
pubmed: 27269199
doi: 10.1016/j.pscychresns.2016.04.016
Offord SJ, Ordway GA, Frazer A. Application of [125I]iodocyanopindolol to measure 5-hydroxytryptamine1B receptors in the brain of the rat. J Pharm Exp Ther. 1988;244:144 LP–153.
Verge D, Daval G, Marcinkiewicz M, Patey A, el Mestikawy S, Gozlan H, et al. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci. 1986;6:3474 LP–3482.
doi: 10.1523/JNEUROSCI.06-12-03474.1986
Dell LE, Parsons LH. Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J Pharm Exp Ther. 2004;311:711 LP–719.
doi: 10.1124/jpet.104.069278
Yan Q-S, Zheng S-Z, Yan S-E. Involvement of 5-HT1B receptors within the ventral tegmental area in regulation of mesolimbic dopaminergic neuronal activity via GABA mechanisms: a study with dual-probe microdialysis. Brain Res. 2004;1021:82–91.
pubmed: 15328035
doi: 10.1016/j.brainres.2004.06.053